Skip to main content

Doctors should no longer routinely prescribe medication to treat osteoporosis in patients with low bone-mineral density and no other risk factors for the disease, according to Suzanne Morin, co-author of new guidelines released by Osteoporosis Canada.

The guidelines coincided with a recent warning by Health Canada about a possible increased risk of a rare type of thigh-bone fracture in patients using bone-strengthening drugs known as bisphosphonates.

Symptoms of an atypical fracture to the thigh bone include a new or unusual pain in the groin, hip or thigh area.

Story continues below advertisement

The U.S. Food and Drug Administration recently announced a change to the warning labels for bisphosphonate drugs. Brand names of the medications include Aclasta (zoledronic acid), Actonel (risedronate), Didrocal (etidronate) and Fosamax (alendronate).

Regulatory bodies in Canada and the U.S. emphasized that it is unclear whether bisphosphonates are the cause of atypical thigh-bone fractures.

The optimal duration of bisphosphonate treatment for osteoporosis is unknown. Nevertheless, patients at high risk for osteoporosis should continue to take medication until a doctor advises them to stop, Dr. Morin says. "Obviously, the benefits in that population outweigh these very small risks," she adds.

Report an error Licensing Options
About the Author

Adriana Barton is based in The Globe and Mail’s Vancouver bureau. Her article on growing up with counterculture parents is published in a McGraw-Hill anthology, right after an essay by Margaret Atwood. She wishes her last name didn’t start with B. More

Comments are closed

We have closed comments on this story for legal reasons. For more information on our commenting policies and how our community-based moderation works, please read our Community Guidelines and our Terms and Conditions.